Victoria Shapiro
[email protected]
(202) 414-0774
WASHINGTON (November 15, 2012) – LUNGevity Foundation has issued three Requests for Applications (RFAs) for translational research for the following Awards that will be granted in 2013: Career Development Awards, Early Detection Awards, and Targeted Therapeutics Awards. The RFAs are available on the LUNGevity website at www.lungevity.org/research and are also posted on the proposalCENTRAL website.
LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. “It is essential to attract and keep talented researchers in the field of lung cancer research,” said Andrea Stern Ferris, President of LUNGevity Foundation. Successful applicants will receive $100,000 per year for a possible period of three years and will participate as non-voting members of LUNGevity’s Scientific Advisory Board for the duration of the award.
LUNGevity Early Detection Awards support research projects directed at new approaches to improve clinical methods for the early detection and diagnosis of lung cancer. The preference is for studies that are likely to result in patient benefit in the foreseeable future. LUNGevity Targeted Therapeutics Awards support research projects directed at the discovery and validation of biomarkers or novel targeted therapeutics that will make a difference in the clinical treatment and survival of patients.
Applicants for either Early Detection or Targeted Therapeutics Awards may apply as individuals or in teams of up to three investigators. It is strongly encouraged that teams be composed of principal investigators from different institutions. Successful projects will be funded at $100,000 per investigator per year for a maximum possible award of $600,000 over two years.
LUNGevity supports the largest research awards program of any lung cancer-focused organization in the United States. LUNGevity-funded research projects since 2002 total more than $14 million, representing 92 projects at 54 institutions in 23 states.
About LUNGevity Foundation
The mission of LUNGevity Foundation is to have a meaningful impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients and provide a community for those impacted by lung cancer. It does so by supporting critical research into the early detection and successful treatment of lung cancer, as well as by providing information, resources and a support community to patients and caregivers.
LUNGevity seeks to inspire the nation to commit to ending lung cancer.
For more information about the grants or LUNGevity Foundation, please visit www.lungevity.org.
About Lung Cancer
- 1 in 14 Americans is diagnosed with lung cancer in their lifetime
- Lung cancer is the leading cause of cancer death, regardless of gender or ethnicity
- Lung cancer kills almost twice as many women as breast cancer and more than three times as many men as prostate cancer
- About 55% of all new lung cancer diagnoses are among people who have never smoked or are former smokers
- Only 16% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it’s caught before it spreads, the chance for 5-year survival improves dramatically